DocMorris AG
DocMorris AG operates as an online pharmacy, telemedicine, and healthcare company in Switzerland and internationally. It offers prescription and over-the-counter medicines, and consumer health products, as well as beauty and personal care products, nutritional supplements, painkillers, and first aid products. The company also provides professional health care services to doctors, pharmacies, insu… Read more
DocMorris AG (DOCM) - Net Assets
Latest net assets as of June 2025: CHF480.35 Million CHF
Based on the latest financial reports, DocMorris AG (DOCM) has net assets worth CHF480.35 Million CHF as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CHF907.44 Million) and total liabilities (CHF427.09 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CHF480.35 Million |
| % of Total Assets | 52.93% |
| Annual Growth Rate | 9.26% |
| 5-Year Change | -36.04% |
| 10-Year Change | 367.34% |
| Growth Volatility | 49.88 |
DocMorris AG - Net Assets Trend (2009–2024)
This chart illustrates how DocMorris AG's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for DocMorris AG (2009–2024)
The table below shows the annual net assets of DocMorris AG from 2009 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CHF340.11 Million | -21.00% |
| 2023-12-31 | CHF430.53 Million | +22.74% |
| 2022-12-31 | CHF350.78 Million | -27.66% |
| 2021-12-31 | CHF484.92 Million | -8.80% |
| 2020-12-31 | CHF531.74 Million | +31.12% |
| 2019-12-31 | CHF405.54 Million | -8.58% |
| 2018-12-31 | CHF443.61 Million | +50.77% |
| 2017-12-31 | CHF294.22 Million | +183.44% |
| 2016-12-31 | CHF103.81 Million | +42.64% |
| 2015-12-31 | CHF72.78 Million | -5.91% |
| 2014-12-31 | CHF77.35 Million | +5.41% |
| 2013-12-31 | CHF73.38 Million | -14.47% |
| 2012-12-31 | CHF85.79 Million | +4.88% |
| 2011-12-31 | CHF81.80 Million | +3.29% |
| 2010-12-31 | CHF79.19 Million | -12.14% |
| 2009-12-31 | CHF90.14 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to DocMorris AG's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1689.9% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | CHF445.05 Million | 130.85% |
| Other Comprehensive Income | CHF582.55 Million | 171.28% |
| Total Equity | CHF340.11 Million | 100.00% |
DocMorris AG Competitors by Market Cap
The table below lists competitors of DocMorris AG ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Prenetics Global Ltd
NASDAQ:PRE
|
$222.02 Million |
|
Samyang Holdings Corp
KO:000075
|
$222.02 Million |
|
ProFrac Holding Corp.
NASDAQ:ACDC
|
$222.04 Million |
|
Anhui Wanyi Science and Technology Co Ltd
SHG:688600
|
$222.05 Million |
|
Eagle Bulk Shipping Inc
NYSE:EGLE
|
$221.96 Million |
|
Taiyuan Lionhead Cement Co Ltd
SHG:600539
|
$221.90 Million |
|
Shanghai Nenghui Technology Co.Ltd
SHE:301046
|
$221.90 Million |
|
Teraplast Bist
RO:TRP
|
$221.89 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in DocMorris AG's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 430,532,000 to 340,114,000, a change of -90,418,000 (-21.0%).
- Net loss of 97,253,000 reduced equity.
- Share repurchases of 73,000 reduced equity.
- Other comprehensive income increased equity by 2,621,000.
- Other factors increased equity by 4,287,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CHF-97.25 Million | -28.59% |
| Share Repurchases | CHF73.00K | -0.02% |
| Other Comprehensive Income | CHF2.62 Million | +0.77% |
| Other Changes | CHF4.29 Million | +1.26% |
| Total Change | CHF- | -21.00% |
Book Value vs Market Value Analysis
This analysis compares DocMorris AG's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.16x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 0.27x to 0.16x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2010-12-31 | CHF17.46 | CHF4.74 | x |
| 2011-12-31 | CHF25.67 | CHF4.74 | x |
| 2012-12-31 | CHF26.85 | CHF4.74 | x |
| 2013-12-31 | CHF21.68 | CHF4.74 | x |
| 2014-12-31 | CHF22.86 | CHF4.74 | x |
| 2015-12-31 | CHF21.44 | CHF4.74 | x |
| 2016-12-31 | CHF22.89 | CHF4.74 | x |
| 2017-12-31 | CHF56.35 | CHF4.74 | x |
| 2018-12-31 | CHF69.87 | CHF4.74 | x |
| 2019-12-31 | CHF46.82 | CHF4.74 | x |
| 2020-12-31 | CHF58.58 | CHF4.74 | x |
| 2021-12-31 | CHF50.28 | CHF4.74 | x |
| 2022-12-31 | CHF32.55 | CHF4.74 | x |
| 2023-12-31 | CHF36.88 | CHF4.74 | x |
| 2024-12-31 | CHF28.84 | CHF4.74 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently DocMorris AG utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -28.59%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -9.56%
- • Asset Turnover: 1.31x
- • Equity Multiplier: 2.29x
- Recent ROE (-28.59%) is below the historical average (-10.73%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2010 | 4.95% | 0.80% | 3.36x | 1.83x | CHF-4.00 Million |
| 2011 | 10.60% | 1.78% | 3.37x | 1.77x | CHF494.00K |
| 2012 | 7.18% | 1.18% | 1.97x | 3.10x | CHF-2.42 Million |
| 2013 | -21.07% | -1.70% | 4.05x | 3.07x | CHF-22.80 Million |
| 2014 | 9.25% | 0.78% | 4.01x | 2.95x | CHF-581.10K |
| 2015 | 4.73% | 0.41% | 3.57x | 3.21x | CHF-3.83 Million |
| 2016 | -12.30% | -1.45% | 3.36x | 2.52x | CHF-23.15 Million |
| 2017 | -12.33% | -3.69% | 2.15x | 1.55x | CHF-65.64 Million |
| 2018 | -8.79% | -3.23% | 1.66x | 1.64x | CHF-83.33 Million |
| 2019 | -12.91% | -3.86% | 1.37x | 2.44x | CHF-92.92 Million |
| 2020 | -25.52% | -9.19% | 1.16x | 2.40x | CHF-188.87 Million |
| 2021 | -46.55% | -13.07% | 1.36x | 2.62x | CHF-274.23 Million |
| 2022 | -48.78% | -18.38% | 0.85x | 3.13x | CHF-206.19 Million |
| 2023 | 19.11% | 8.49% | 1.12x | 2.01x | CHF39.23 Million |
| 2024 | -28.59% | -9.56% | 1.31x | 2.29x | CHF-131.26 Million |
Industry Comparison
This section compares DocMorris AG's net assets metrics with peer companies in the Pharmaceutical Retailers industry.
No peer company data available for comparison.